Peter Pushko

Summary

Publications

  1. ncbi Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus
    Peter Pushko
    Novavax, Inc, 9920 Belward Campus Drive, Rockville, MD 20850, USA
    Vaccine 28:4771-6. 2010
  2. ncbi Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza
    Peter Pushko
    Novavax Inc, 9920 Belward Campus Drive, Rockville, MD 20850, USA
    Vaccine 25:4283-90. 2007
  3. ncbi Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle
    Rick A Bright
    Novavax, Inc, Rockville, Maryland, USA
    PLoS ONE 3:e1501. 2008
  4. ncbi Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin
    Rick A Bright
    Novavax, Inc, Rockville, MD 20850, USA
    Vaccine 25:3871-8. 2007
  5. ncbi Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes
    Peter Pushko
    Medigen, Inc, 4539 Metropolitan Court, Frederick, MD, USA
    Vaccine 29:5911-8. 2011
  6. ncbi Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice
    Peter Pushko
    Novavax, Inc, Vaccine Technologies, 1 Taft Court, Rockville, MD 20850, USA
    Vaccine 23:5751-9. 2005

Detail Information

Publications6

  1. ncbi Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus
    Peter Pushko
    Novavax, Inc, 9920 Belward Campus Drive, Rockville, MD 20850, USA
    Vaccine 28:4771-6. 2010
    ..Moreover, a single 15mug dose of H1N1 VLPs resulted in complete virus clearance in the ferret lung. These results provide support for the use of recombinant influenza VLP vaccine as an effective strategy against pandemic H1N1 virus...
  2. ncbi Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza
    Peter Pushko
    Novavax Inc, 9920 Belward Campus Drive, Rockville, MD 20850, USA
    Vaccine 25:4283-90. 2007
    ..Positive effect of the adjuvant was also detected using the rH9 vaccine. The results have implications for the development of safe and effective vaccines for avian influenza viruses with pandemic potential...
  3. ncbi Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle
    Rick A Bright
    Novavax, Inc, Rockville, Maryland, USA
    PLoS ONE 3:e1501. 2008
    ....
  4. ncbi Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin
    Rick A Bright
    Novavax, Inc, Rockville, MD 20850, USA
    Vaccine 25:3871-8. 2007
    ..Interestingly, VLPs elicited antibodies that recognized a broader panel of antigenically distinct H3N2 viral isolates compared to rHA or WIV in a hemagglutination-inhibition (HAI) assay...
  5. ncbi Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes
    Peter Pushko
    Medigen, Inc, 4539 Metropolitan Court, Frederick, MD, USA
    Vaccine 29:5911-8. 2011
    ..We conclude that this technology may represent a novel strategy for rapid development of trivalent seasonal and pandemic vaccines...
  6. ncbi Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice
    Peter Pushko
    Novavax, Inc, Vaccine Technologies, 1 Taft Court, Rockville, MD 20850, USA
    Vaccine 23:5751-9. 2005
    ..Thus, VLPs represent a potential strategy for the development of human vaccines against avian influenza H9N2 viruses...